BR0207681A - Combinações sinérgicas de ligantes do receptor retinóide e agentes citotóxicos selecionados para tratamento do câncer - Google Patents

Combinações sinérgicas de ligantes do receptor retinóide e agentes citotóxicos selecionados para tratamento do câncer

Info

Publication number
BR0207681A
BR0207681A BR0207681-0A BR0207681A BR0207681A BR 0207681 A BR0207681 A BR 0207681A BR 0207681 A BR0207681 A BR 0207681A BR 0207681 A BR0207681 A BR 0207681A
Authority
BR
Brazil
Prior art keywords
cytotoxic agents
cancer treatment
retinoid receptor
selected cytotoxic
receptor ligands
Prior art date
Application number
BR0207681-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Valerie Sandrine Vivat-Hannah
Matthew V Lorenzi
Marco M Gottardis
Fred Christopher Zusi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0207681A publication Critical patent/BR0207681A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0207681-0A 2001-03-22 2002-03-22 Combinações sinérgicas de ligantes do receptor retinóide e agentes citotóxicos selecionados para tratamento do câncer BR0207681A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27775401P 2001-03-22 2001-03-22
PCT/US2002/008718 WO2002078620A2 (en) 2001-03-22 2002-03-22 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer

Publications (1)

Publication Number Publication Date
BR0207681A true BR0207681A (pt) 2004-07-27

Family

ID=23062213

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207681-0A BR0207681A (pt) 2001-03-22 2002-03-22 Combinações sinérgicas de ligantes do receptor retinóide e agentes citotóxicos selecionados para tratamento do câncer

Country Status (15)

Country Link
EP (1) EP1383491A2 (https=)
JP (1) JP2004528316A (https=)
KR (1) KR20030086314A (https=)
CN (1) CN1498105A (https=)
BR (1) BR0207681A (https=)
CA (1) CA2441335A1 (https=)
CZ (1) CZ20032540A3 (https=)
DE (1) DE02733871T1 (https=)
ES (1) ES2214985T1 (https=)
HU (1) HUP0400255A2 (https=)
IL (1) IL157358A0 (https=)
MX (1) MXPA03008403A (https=)
PL (1) PL368946A1 (https=)
TR (1) TR200400812T3 (https=)
WO (1) WO2002078620A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113038B2 (ja) * 2006-03-23 2013-01-09 テムリック株式会社 癌治療用キットおよび癌治療用医薬組成物

Also Published As

Publication number Publication date
CN1498105A (zh) 2004-05-19
PL368946A1 (pl) 2005-04-04
IL157358A0 (en) 2004-02-19
HUP0400255A2 (hu) 2004-08-30
KR20030086314A (ko) 2003-11-07
DE02733871T1 (de) 2004-08-26
TR200400812T3 (tr) 2004-07-21
ES2214985T1 (es) 2004-10-01
JP2004528316A (ja) 2004-09-16
WO2002078620A2 (en) 2002-10-10
CA2441335A1 (en) 2002-10-10
CZ20032540A3 (cs) 2004-05-12
WO2002078620A3 (en) 2003-04-17
MXPA03008403A (es) 2004-01-29
EP1383491A2 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
EP1423107A4 (en) FATTY ALCOHOL DRUG CONJUGATES
MXPA97002401A (es) Agente antiinflamatorio para uso externo.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
MXPA02011099A (es) Dispositivos de suministro para tratamiento de enfermedades vasculares.
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
EP0960107A4 (https=)
MXPA03007140A (es) Derivados de carbolina.
DE69808130D1 (de) Adamantan-derivate
TR200100054T2 (tr) Paroksetin metansülfonat
IL149402A0 (en) Arylamine derivatives and their use as anti-telomerase agent
EP1053010A4 (en) COPOLYMER COMPOSITIONS FOR ORAL ADMINISTRATION
EP1140198A4 (en) COMPOSITION FOR INCREASING THE EFFECTIVENESS OF MEDICINES AND RELATED METHODS
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
ID24184A (id) Obat untuk perawatan disfungsi ereksi
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
BR0207681A (pt) Combinações sinérgicas de ligantes do receptor retinóide e agentes citotóxicos selecionados para tratamento do câncer
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]